Ascendiant Capital Initiates Coverage of Cyclo Therapeutics (CYTH) with Buy Recommendation

Fintel reports that on April 22, 2024, Ascendiant Capital initiated coverage of Cyclo Therapeutics (NasdaqCM:CYTH) with a Buy recommendation.

Analyst Price Forecast Suggests 251.72% Upside

As of April 17, 2024, the average one-year price target for Cyclo Therapeutics is 4.08. The forecasts range from a low of 4.04 to a high of $4.20. The average price target represents an increase of 251.72% from its latest reported closing price of 1.16.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Cyclo Therapeutics is 6MM, an increase of 440.97%. The projected annual non-GAAP EPS is -0.79.

What is the Fund Sentiment?

There are 33 funds or institutions reporting positions in Cyclo Therapeutics. This is an increase of 9 owner(s) or 37.50% in the last quarter. Average portfolio weight of all funds dedicated to CYTH is 2.35%, an increase of 1,106,200.35%. Total shares owned by institutions increased in the last three months by 190.92% to 1,399K shares. CYTH / Cyclo Therapeutics, Inc. Put/Call Ratios The put/call ratio of CYTH is 0.00, indicating a bullish outlook.

What are Other Shareholders Doing?

CYTH / Cyclo Therapeutics, Inc. Shares Held by Institutions

Founders Fund V Management holds 481K shares representing 1.67% ownership of the company.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 177K shares representing 0.62% ownership of the company. No change in the last quarter.

VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 153K shares representing 0.53% ownership of the company. No change in the last quarter.

Geode Capital Management holds 152K shares representing 0.53% ownership of the company. In it's prior filing, the firm reported owning 101K shares, representing an increase of 33.91%. The firm increased its portfolio allocation in CYTH by 48.79% over the last quarter.

Founders Fund VI Management holds 110K shares representing 0.38% ownership of the company.

Cyclo Therapeutics Background Information
(This description is provided by the company.)

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, ( NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.